The Administrative Core (Core A) will serve as a centralized facility designed to manage all operations related to this PP and facilitate the interactions between the collaborating laboratories. The major tasks of this Core component will be to: a) communicate the central scientific theme to which all component projects will direct their research efforts; b) manage the fiscal aspects of the PP, maintain financial records and other administrative functions; and (c) promptly and properly distribute or coordinate the distribution of materials (chemicals, biologicals, ligands, radioligands, receptor mutants, antibodies, clones, etc.) produced under the auspices of Core B and the other projects. The Administrative Core will also take responsibility for synchronizing the operations and communications between the individual laboratories involved in the PP and other laboratories which interact collaboratively at no cost to the project. This effort will include recording and distributing materials produced to the participant laboratories and to the collaborating laboratories, together with maintaining and updating the data base related to this collaborative effort. Additional specific coordinating efforts will include regular telephone conferences, the yearly group meeting of participants and collaborators, as well as other communications, including the maintenance of a Web page dedicated to Program Project activities. The quarterly meetings with the Internal Advisory Committee, as well as the yearly formal meeting with the External Scientific Advisory Committee, will also be organized under Core A. The Administrative Core will maintain or increase the common or shared resources that are required for the performance of the inter-related tasks for the component research projects. General administrative support related to this Program Project, including financial management, correspondence, and preparation of reports and proposals, will also be provided by this Core Facility. The Core A proposal also includes a brief summary of all of the Program Project components and an outline of the scientific interactions between the participating laboratories, including lines of authority, program coordination and evaluation. The synergistic aspect of the different collaborations, all working in this specialized area of mutual scientific and public health interest, constitutes a major strength of this unique multidisciplinary research effort.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Program Projects (P01)
Project #
2P01DA009158-10
Application #
7222482
Study Section
Special Emphasis Panel (ZDA1-RXL-E (16))
Project Start
2007-05-15
Project End
2012-04-30
Budget Start
2007-05-15
Budget End
2008-04-30
Support Year
10
Fiscal Year
2007
Total Cost
$51,002
Indirect Cost
Name
Northeastern University
Department
Type
DUNS #
001423631
City
Boston
State
MA
Country
United States
Zip Code
02115
Lin, Xiaoyan; Dhopeshwarkar, Amey S; Huibregtse, Megan et al. (2018) Slowly Signaling G Protein-Biased CB2 Cannabinoid Receptor Agonist LY2828360 Suppresses Neuropathic Pain with Sustained Efficacy and Attenuates Morphine Tolerance and Dependence. Mol Pharmacol 93:49-62
Slivicki, Richard A; Saberi, Shahin A; Iyer, Vishakh et al. (2018) Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit. J Pharmacol Exp Ther 367:551-563
Straiker, Alex; Dvorakova, Michaela; Zimmowitch, Anaelle et al. (2018) Cannabidiol Inhibits Endocannabinoid Signaling in Autaptic Hippocampal Neurons. Mol Pharmacol 94:743-748
Mallipeddi, Srikrishnan; Zvonok, Nikolai; Makriyannis, Alexandros (2018) Expression, Purification and Characterization of the Human Cannabinoid 1 Receptor. Sci Rep 8:2935
Slivicki, Richard A; Xu, Zhili; Kulkarni, Pushkar M et al. (2018) Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence. Biol Psychiatry 84:722-733
Li, Ai-Ling; Carey, Lawrence M; Mackie, Ken et al. (2017) Cannabinoid CB2 Agonist GW405833 Suppresses Inflammatory and Neuropathic Pain through a CB1 Mechanism that is Independent of CB2 Receptors in Mice. J Pharmacol Exp Ther 362:296-305
Finlay, David B; Cawston, Erin E; Grimsey, Natasha L et al. (2017) G?s signalling of the CB1 receptor and the influence of receptor number. Br J Pharmacol 174:2545-2562
Ruehle, Sabine; Wager-Miller, James; Straiker, Alex et al. (2017) Discovery and characterization of two novel CB1 receptor splice variants with modified N-termini in mouse. J Neurochem 142:521-533
Hua, Tian; Vemuri, Kiran; Nikas, Spyros P et al. (2017) Crystal structures of agonist-bound human cannabinoid receptor CB1. Nature 547:468-471
Dhopeshwarkar, Amey; Murataeva, Natalia; Makriyannis, Alex et al. (2017) Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists. J Pharmacol Exp Ther 360:300-311

Showing the most recent 10 out of 196 publications